WILLIAM BARRY WHITE

Summary

Affiliation: University of Connecticut Health Center
Country: USA

Publications

  1. ncbi request reprint Pharmacologic agents in the management of hypertension--nisoldipine coat-core
    William B White
    Division of Hypertension and Clinical Pharmacology, Pat and Jim Calhoun Cardiology Center, University of Connecticut School of Medicine, Farmington, CT 06030 3940, USA
    J Clin Hypertens (Greenwich) 9:259-66. 2007
  2. pmc Long-term reproducibility of ambulatory blood pressure is superior to office blood pressure in the very elderly
    P Campbell
    Division of Hypertension and Clinical Pharmacology, Calhoun Cardiology Center, University of Connecticut School of Medicine, Farmington, CT, USA
    J Hum Hypertens 24:749-54. 2010
  3. pmc Effects of Telmisartan with Hydrochlorothiazide versus Valsartan with Hydrochlorothiazide in Patients with Moderate-to-Severe Hypertension
    Ravi Marfatia
    Division of Hypertension and Clinical Pharmacology, Pat and Jim Calhoun Cardiology Center, University of Connecticut School of Medicine, Farmington, CT 06030, USA
    Int J Hypertens 2012:976828. 2012
  4. ncbi request reprint Alogliptin after acute coronary syndrome in patients with type 2 diabetes
    William B White
    Calhoun Cardiology Center, Department of Medicine, University of Connecticut School of Medicine, 263 Farmington Ave, Farmington, CT 06030 3940, USA
    N Engl J Med 369:1327-35. 2013
  5. doi request reprint Cardiovascular safety of the dipetidyl peptidase-4 inhibitor alogliptin in type 2 diabetes mellitus
    W B White
    Calhoun Cardiology Center, University of Connecticut School of Medicine, Farmington, CT 06030, USA
    Diabetes Obes Metab 15:668-73. 2013
  6. pmc INtensive versus standard ambulatory blood pressure lowering to prevent functional DeclINe in the ElderlY (INFINITY)
    William B White
    University of Connecticut School of Medicine, Farmington, CT, USA
    Am Heart J 165:258-265.e1. 2013
  7. doi request reprint Cardiovascular safety of febuxostat and allopurinol in patients with gout and cardiovascular comorbidities
    William B White
    University of Connecticut School of Medicine, Farmington, 06030 3940, USA
    Am Heart J 164:14-20. 2012
  8. doi request reprint Is it possible to manage hypertension and evaluate therapy without ambulatory blood pressure monitoring?
    William B White
    Division of Hypertension and Clinical Pharmacology, Pat and Jim Calhoun Cardiology Center, University of Connecticut School of Medicine, 263 Farmington Avenue, Farmington, CT 06032 3940, USA
    Curr Hypertens Rep 14:366-73. 2012
  9. ncbi request reprint Improving blood pressure control: increase the dose of diuretic or switch to a fixed-dose angiotensin receptor blocker/diuretic? the valsartan hydrochlorothiazide diuretic for initial control and titration to achieve optimal therapeutic effect (Val-DICTAT
    William B White
    Division of Hypertension and Clinical Pharmacology, Pat and Jim Calhoun Cardiology Center, University of Connecticut School of Medicine, Farmington, CT, USA
    J Clin Hypertens (Greenwich) 10:450-8. 2008
  10. ncbi request reprint Update on the drug treatment of hypertension in patients with cardiovascular disease
    William B White
    Division of Hypertension and Clinical Pharmacology, Pat and Jim Calhoun Center of Cardiology, University of Connecticut School of Medicine, Farmington, CT 06030 3940, USA
    Am J Med 118:695-705. 2005

Research Grants

Collaborators

Detail Information

Publications99

  1. ncbi request reprint Pharmacologic agents in the management of hypertension--nisoldipine coat-core
    William B White
    Division of Hypertension and Clinical Pharmacology, Pat and Jim Calhoun Cardiology Center, University of Connecticut School of Medicine, Farmington, CT 06030 3940, USA
    J Clin Hypertens (Greenwich) 9:259-66. 2007
    ..Thus, results of more than a decade of clinical trial data support the use of nisoldipine CC as once-daily therapy for the treatment of hypertension...
  2. pmc Long-term reproducibility of ambulatory blood pressure is superior to office blood pressure in the very elderly
    P Campbell
    Division of Hypertension and Clinical Pharmacology, Calhoun Cardiology Center, University of Connecticut School of Medicine, Farmington, CT, USA
    J Hum Hypertens 24:749-54. 2010
    ..In a clinical trial involving this age group, far fewer subjects would be required if 24-h BP was the primary efficacy endpoint rather than the office BP...
  3. pmc Effects of Telmisartan with Hydrochlorothiazide versus Valsartan with Hydrochlorothiazide in Patients with Moderate-to-Severe Hypertension
    Ravi Marfatia
    Division of Hypertension and Clinical Pharmacology, Pat and Jim Calhoun Cardiology Center, University of Connecticut School of Medicine, Farmington, CT 06030, USA
    Int J Hypertens 2012:976828. 2012
    ..These findings support the use of longer-acting ARBs combined with higher doses of thiazide diuretic to improve BP control in patients with moderate-to-severe hypertension...
  4. ncbi request reprint Alogliptin after acute coronary syndrome in patients with type 2 diabetes
    William B White
    Calhoun Cardiology Center, Department of Medicine, University of Connecticut School of Medicine, 263 Farmington Ave, Farmington, CT 06030 3940, USA
    N Engl J Med 369:1327-35. 2013
    ..We assessed cardiovascular outcomes with alogliptin, a new inhibitor of dipeptidyl peptidase 4 (DPP-4), as compared with placebo in patients with type 2 diabetes who had had a recent acute coronary syndrome...
  5. doi request reprint Cardiovascular safety of the dipetidyl peptidase-4 inhibitor alogliptin in type 2 diabetes mellitus
    W B White
    Calhoun Cardiology Center, University of Connecticut School of Medicine, Farmington, CT 06030, USA
    Diabetes Obes Metab 15:668-73. 2013
    ..As there have been concerns that some classes or agents for the treatment of type 2 diabetes may increase CV risk, we evaluated the cardiovascular profile of the dipeptidyl peptidase-4 inhibitor alogliptin...
  6. pmc INtensive versus standard ambulatory blood pressure lowering to prevent functional DeclINe in the ElderlY (INFINITY)
    William B White
    University of Connecticut School of Medicine, Farmington, CT, USA
    Am Heart J 165:258-265.e1. 2013
    ..The INFINITY trial is the first to guide antihypertensive therapy using ABP monitoring rather than clinic BP to reduce cerebrovascular disease...
  7. doi request reprint Cardiovascular safety of febuxostat and allopurinol in patients with gout and cardiovascular comorbidities
    William B White
    University of Connecticut School of Medicine, Farmington, 06030 3940, USA
    Am Heart J 164:14-20. 2012
    ..The CARES trial will define the CV safety profile of febuxostat and allopurinol in gout patients at high risk for CV events...
  8. doi request reprint Is it possible to manage hypertension and evaluate therapy without ambulatory blood pressure monitoring?
    William B White
    Division of Hypertension and Clinical Pharmacology, Pat and Jim Calhoun Cardiology Center, University of Connecticut School of Medicine, 263 Farmington Avenue, Farmington, CT 06032 3940, USA
    Curr Hypertens Rep 14:366-73. 2012
    ..In this review, we summarize the clinical importance of ABPM and discuss the current guidelines for establishing the diagnosis of hypertension...
  9. ncbi request reprint Improving blood pressure control: increase the dose of diuretic or switch to a fixed-dose angiotensin receptor blocker/diuretic? the valsartan hydrochlorothiazide diuretic for initial control and titration to achieve optimal therapeutic effect (Val-DICTAT
    William B White
    Division of Hypertension and Clinical Pharmacology, Pat and Jim Calhoun Cardiology Center, University of Connecticut School of Medicine, Farmington, CT, USA
    J Clin Hypertens (Greenwich) 10:450-8. 2008
    ..This study suggests that in the management of hypertension, utilizing an angiotensin receptor blocker/diuretic combination was more effective in lowering BP and achieving BP goals when compared with increasing the dose of the diuretic...
  10. ncbi request reprint Update on the drug treatment of hypertension in patients with cardiovascular disease
    William B White
    Division of Hypertension and Clinical Pharmacology, Pat and Jim Calhoun Center of Cardiology, University of Connecticut School of Medicine, Farmington, CT 06030 3940, USA
    Am J Med 118:695-705. 2005
    ....
  11. ncbi request reprint Cardiovascular effects of the selective cyclooxygenase-2 inhibitors
    William B White
    Division of Hypertension and Clinical Pharmacology, Pat and Jim Calhoun Cardiology Center, University of Connecticut School of Medicine, 263 Farmington Avenue, Farmington, Connecticut 06030 3940, USA
    Subcell Biochem 42:145-58. 2007
    ....
  12. ncbi request reprint Ambulatory blood pressure monitoring in the primary care setting: assessment of therapy on the circadian variation of blood pressure from the MICCAT-2 Trial
    William B White
    Division of Hypertension and Clinical Pharmacology, Pat and Jim Calhoun Cardiology Center, University of Connecticut School of Medicine, Farmington, Connecticut 06030 3940, USA
    Blood Press Monit 10:157-63. 2005
    ....
  13. ncbi request reprint Treatment of benign prostatic hyperplasia in hypertensive men
    William B White
    Section of Hypertension and Clinical Pharmacology, Center for Cardiology and Cardiovascular Biology, University of Connecticut School of Medicine, Farmington, CT 06030 3940, USA
    J Clin Hypertens (Greenwich) 7:212-7. 2005
    ....
  14. ncbi request reprint Transtelephonic home blood pressure to assess the monoamine oxidase-B inhibitor rasagiline in Parkinson disease
    William B White
    Division of Hypertension and Clinical Pharmacology, Pat and Jim Calhoun Cardiology Center and Clinical Trials Unit, University of Connecticut, Farmington, Connecticut 06030 3940, USA
    Hypertension 52:587-93. 2008
    ..3%, 2.6%, and 2.9% of the placebo, 0.5-mg, and 1.0-mg rasagiline groups, respectively. These data demonstrate that rasagiline did not induce postprandial hypertension in patients with Parkinson disease who were on an unrestricted diet...
  15. doi request reprint Impact of angiotensin receptor blockade in combination with hydrochlorothiazide 25 mg in 2121 patients with stage 1-2 hypertension
    W B White
    Division of Hypertension and Clinical Pharmacology, Pat and Jim Calhoun Cardiology Center, University of Connecticut School of Medicine, Farmington, CT 06030, USA
    J Hum Hypertens 23:817-25. 2009
    ..The magnitude of the BP-lowering effect provides support for the use of angiotensin receptor blockers with higher doses of a thiazide diuretic (25 mg) to improve hypertension control...
  16. doi request reprint Defining the problem of treating the patient with hypertension and arthritis pain
    William B White
    Division of Hypertension and Clinical Pharmacology, Pat and Jim Calhoun Cardiology Center, University of Connecticut School of Medicine, Farmington, Connecticut 06030 3940, USA
    Am J Med 122:S3-9. 2009
    ....
  17. ncbi request reprint Measuring the efficacy of antihypertensive therapy by ambulatory blood pressure monitoring in the primary care setting
    William B White
    Division of Hypertension and Clinical Pharmacology, Pat and Jim Calhoun Cardiology Center, University of Connecticut School of Medicine, Farmington, CT, USA
    Am Heart J 151:176-84. 2006
    ..Therefore, we used ambulatory blood pressure monitoring (ABPM), an automated and objective measure of blood pressure (BP) to overcome these shortcomings in a large community-based trial...
  18. ncbi request reprint Effects of graded-release diltiazem versus ramipril, dosed at bedtime, on early morning blood pressure, heart rate, and the rate-pressure product
    William B White
    Section of Hypertension and Clinical Pharmacology, University of Connecticut School of Medicine, Farmington, Conn 06030 3940, USA
    Am Heart J 148:628-34. 2004
    ..Therapeutic agents for the treatment of hypertension may differ in their efficacy during the early morning period, a time when both morbid and mortal cardiovascular events are increased compared to other times of the day...
  19. doi request reprint Effects of the cyclooxygenase inhibiting nitric oxide donator naproxcinod versus naproxen on systemic blood pressure in patients with osteoarthritis
    William B White
    Pat and Jim Calhoun Cardiology Center, University of Connecticut School of Medicine, Farmington, Connecticut, USA
    Am J Cardiol 104:840-5. 2009
    ..04), naproxcinod 375 mg (14%, p = 0.055), and placebo (15.6%, p = 0.155). In conclusion, naproxcinod did not induce elevations of BP seen with naproxen, and it had similar effects on BP to that of placebo in patients with osteoarthritis...
  20. ncbi request reprint Smoking-related morbidity and mortality in the cardiovascular setting
    William B White
    Division of Hypertension and Clinical Pharmacology, Pat and Jim Calhoun Cardiology Center, University of Connecticut School of Medicine, Farmington, CT 06030 3940, USA
    Prev Cardiol 10:1-4. 2007
    ..These latest findings should stimulate efforts of health care workers to become more aggressive toward cessation of smoking in our practices...
  21. ncbi request reprint Antihypertensive effects of drospirenone with 17beta-estradiol, a novel hormone treatment in postmenopausal women with stage 1 hypertension
    William B White
    Pat and Jim Calhoun Cardiology Center, University of Connecticut School of Medicine, Farmington, CT 06030 3940, USA
    Circulation 112:1979-84. 2005
    ..In prior studies with DRSP in postmenopausal women that were focused on relief of menopausal symptoms, DRSP/E2 yielded significant reductions in blood pressure (BP)...
  22. ncbi request reprint Importance of blood pressure control over a 24-hour period
    William B White
    Department of Medince, University of Connecticut School of Medicine, Farmington, CT 06030 3940, USA
    J Manag Care Pharm 13:34-9. 2007
    ..Of interest is that cardiovascular (CV) events occur more frequently in the early morning period, the time when BP and heart rate rise steeply...
  23. ncbi request reprint Cardiovascular effects of the cyclooxygenase inhibitors
    William B White
    Division of Hypertension and Clinical Pharmacology, Pat and Jim Calhoun Cardiology Center, University of Connecticut School of Medicine, Farmington, CT 06030 3940, USA
    Hypertension 49:408-18. 2007
  24. ncbi request reprint Ambulatory blood pressure monitoring as an investigative tool for characterizing resistant hypertension and its rational treatment
    William B White
    Division of Hypertension and Clinical Pharmacology, Pat and Jim Calhoun Cardiology Center, University of Connecticut School of Medicine, Farmington, CT 06030 3940, USA
    J Clin Hypertens (Greenwich) 9:25-30. 2007
    ..Evidence is mounting from studies that support the use of ambulatory BP monitoring in patients with resistant hypertension at the time of diagnosis and following clinically guided therapy...
  25. ncbi request reprint Risk of cardiovascular events in patients receiving celecoxib: a meta-analysis of randomized clinical trials
    William B White
    Pat and Jim Calhoun Cardiology Center, University of Connecticut School of Medicine, Farmington, CT, USA
    Am J Cardiol 99:91-8. 2007
    ..In conclusion, these analyses failed to demonstrate an increased CV risk with celecoxib relative to placebo and demonstrated a comparable rate of CV events with celecoxib treatment compared with nonselective NSAIDs...
  26. ncbi request reprint Effects of the angiotensin II receptor blockers telmisartan vs valsartan in combination with hydrochlorothiazide 25 mg once daily for the treatment of hypertension
    William B White
    Division of Hypertension and Clinical Pharmacology, Pat and Jim Calhoun Cardiology Center, University of Connecticut School of Medicine, Farmington, CT 06030 3940, USA
    J Clin Hypertens (Greenwich) 8:626-33. 2006
    ..These data support using a higher dose of a thiazide diuretic (25 mg) with a long-acting angiotensin receptor blocker as a useful strategy for improving hypertension control...
  27. ncbi request reprint Effects of a new hormone therapy, drospirenone and 17-beta-estradiol, in postmenopausal women with hypertension
    William B White
    Division of Hypertension and Clinical Pharmacology, The Pat and Jim Calhoun Cardiology Center, University of Connecticut School of Medicine, 263 Farmington Ave, Farmington, CT 06030 3940, USA
    Hypertension 48:246-53. 2006
    ..These characteristics may lead to a new benefit for this novel hormone therapy in postmenopausal women with hypertension...
  28. ncbi request reprint Cardiovascular risk, hypertension, and NSAIDs
    William B White
    Division of Hypertension and Clinical Pharmacology, Pat and Jim Calhoun Cardiology Center, University of Connecticut School of Medicine, 263 Farmington Avenue, Farmington, CT 06030, USA
    Curr Pain Headache Rep 11:428-35. 2007
    ....
  29. ncbi request reprint Effects of the angiotensin II receptor blockers telmisartan versus valsartan in combination with hydrochlorothiazide: a large, confirmatory trial
    William B White
    Division of Hypertension and Clinical Pharmacology, Pat and Jim Calhoun Cardiology Center, University of Connecticut School of Medicine, Farmington, Connecticut, USA
    Blood Press Monit 13:21-7. 2008
    ..Both studies support the strategy of using angiotensin receptor blockers with a higher dose of a thazide diuretic (25 mg) for enhancing the control of hypertension...
  30. ncbi request reprint Angiotensin-converting enzyme inhibitors in the treatment of hypertension: an update
    William B White
    Pat and Jim Calhoun Cardiology Center, University of Connecticut School of Medicine, Farmington, CT 06030 3940, USA
    J Clin Hypertens (Greenwich) 9:876-82. 2007
    ..Clinical trial data demonstrate that the effectiveness of RAS blockers is enhanced by maximizing the daily dose and combining these medications with thiazide diuretics...
  31. doi request reprint Improving blood pressure control and clinical outcomes through initial use of combination therapy in stage 2 hypertension
    William B White
    Division of Hypertension and Clinical Pharmacology, Pat and Jim Calhoun Cardiology Center, University of Connecticut School of Medicine, Farmington, Connecticut 06030 3940, USA
    Blood Press Monit 13:123-9. 2008
    ..Recent data and treatment guidelines support the use of a combination strategy as 'initial' antihypertensive therapy in high-risk patients with stage 2 hypertension...
  32. ncbi request reprint Acute pain in the tip of the index finger
    William B White
    Pat and Jim Calhoun Cardiology Center, Division of Hypertension and Clinical Pharmacology, University of Connecticut School of Medicine, Farmington, Conn 06030 3940, USA
    Am J Med 118:1223-4. 2005
  33. doi request reprint Utility of semiautomatic clinic and 24-h ambulatory blood pressure measurements to evaluate combination therapy: the Ramipril-Hydrochlorothiazide Hypertension trial
    W B White
    Division of Hypertension and Clinical Pharmacology, Calhoun Cardiology Center, University of Connecticut School of Medicine, Farmington, CT 06030 3940, USA
    J Hum Hypertens 22:559-68. 2008
    ..In conclusion, based on its efficacy and tolerability profile the combination of ramipril and HCT was shown to be effective therapy for the treatment of stage 2 hypertension...
  34. ncbi request reprint Cardiovascular risk, hypertension, and NSAIDs
    William B White
    Division of Hypertension and Clinical Pharmacology, Pat and Jim Calhoun Cardiology Center, University of Connecticut School of Medicine, 263 Farmington Avenue, Farmington, CT 06030 3940, USA
    Curr Rheumatol Rep 9:36-43. 2007
    ....
  35. ncbi request reprint Clinical assessment of early morning blood pressure in patients with hypertension
    William B White
    Division of Hypertension and Clinical Pharmacology, The Pat and Jim Calhoun Cardiology Center, University of Connecticut Health Center, Farmington, CT 06030 3940, USA
    Prev Cardiol 10:210-4. 2007
    ..Given the association between early morning BP and cardiovascular risk, future clinical trials should focus on the efficacy of antihypertensive drugs during this important period of risk...
  36. ncbi request reprint Effects of the cyclooxygenase-2 specific inhibitor valdecoxib versus nonsteroidal antiinflammatory agents and placebo on cardiovascular thrombotic events in patients with arthritis
    William B White
    Division of Hypertension and Clinical Pharmacology, Department of Medicine, University of Connecticut School of Medicine, 263 Farmington Avenue, Farmington, CT 06030 3940, USA
    Am J Ther 11:244-50. 2004
    ....
  37. pmc Safety and tolerability of the direct renin inhibitor aliskiren: a pooled analysis of clinical experience in more than 12,000 patients with hypertension
    William B White
    Calhoun Cardiology Center, University of Connecticut School of Medicine, Farmington, CT 06030 3940, USA
    J Clin Hypertens (Greenwich) 12:765-75. 2010
    ..At the registered doses of 150 mg and 300 mg daily, aliskiren has safety and tolerability profiles similar to placebo, other RAS blockers, and diuretics. Cough rates are lower with aliskiren compared with ACE inhibitors...
  38. doi request reprint Relating cardiovascular risk to out-of-office blood pressure and the importance of controlling blood pressure 24 hours a day
    William B White
    University of Connecticut School of Medicine, Farmington, Connecticut 06030, USA
    Am J Med 121:S2-7. 2008
    ....
  39. ncbi request reprint Clinical utility of ambulatory blood pressure: perspectives for national insurance coverage
    William B White
    Section of Hypertension and Clinical Pharmacology, University of Connecticut School of Medicine, Farmington, Connecticut 06030 3940, USA
    Blood Press Monit 7:27-31. 2002
    ....
  40. ncbi request reprint Effects of celecoxib on ambulatory blood pressure in hypertensive patients on ACE inhibitors
    William B White
    Section of Hypertension and Clinical Pharmacology, University of Connecticut School of Medicine, Farmington, CT 06030 3940, USA
    Hypertension 39:929-34. 2002
    ..The placebo-subtracted changes observed in 24-hour BP (1.6/1.2 mm Hg) are less than what has been reported for nonselective nonsteroidal anti-inflammatory agents in ACE inhibitor-treated patients...
  41. ncbi request reprint Comparison of thromboembolic events in patients treated with celecoxib, a cyclooxygenase-2 specific inhibitor, versus ibuprofen or diclofenac
    William B White
    Section of Hypertension and Clinical Pharmacology, University of Connecticut School of Medicine, Farmington, Connecticut 06030 3940, USA
    Am J Cardiol 89:425-30. 2002
    ....
  42. ncbi request reprint Evaluation of the 24-hour blood pressure effects of eprosartan in patients with systemic hypertension
    W B White
    Section of Hypertension and Clinical Pharmacology, University of Connecticut School of Medicine, Farmington, USA
    Am J Hypertens 14:1248-55. 2001
    ..Although the drug has a relatively short plasma half-life of 5 to 9 h, clinical studies have suggested that its antihypertensive effect persists for 24 h...
  43. ncbi request reprint Gender and age effects on the ambulatory blood pressure and heart rate responses to antihypertensive therapy
    W B White
    University of Connecticut School of Medicine, Farmington, USA
    Am J Hypertens 14:1239-47. 2001
    ....
  44. ncbi request reprint Evaluation of the overall efficacy of the Omron office digital blood pressure HEM-907 monitor in adults
    W B White
    Section of Hypertension and Clinical Pharmacology, University of Connecticut Health Center, Farmington, Connecticut 06030 3940, USA
    Blood Press Monit 6:107-10. 2001
    ..The objective of this study was to assess the accuracy of the HEM-907, a new semi-automatic, non-invasive, oscillometric blood pressure monitoring device specifically designed to be used in the clinic or physician's office setting...
  45. ncbi request reprint Cardiovascular risk and therapeutic intervention for the early morning surge in blood pressure and heart rate
    W B White
    Section of Hypertension and Clinical Pharmacology, University of Connecticut School of Medicine, Farmington, Connecticut 06030 3940, USA
    Blood Press Monit 6:63-72. 2001
    ....
  46. ncbi request reprint The evaluation of antihypertensive therapy using 24-h ambulatory monitoring technology
    W B White
    Section of Hypertension and Clinical Pharmacology, University of Connecticut School of Medicine, Farmington, Connecticut 06030 3940, USA
    Blood Press Monit 5:S13-7. 2000
    ..In this article, an overview of the utility of ambulatory blood pressure monitoring in clinical trials is provided, with specific examples that use data from recent studies of the newer compounds that block the renin-angiotensin system...
  47. ncbi request reprint Ambulatory blood pressure monitoring: dippers compared with non-dippers
    W B White
    University of Connecticut Science Center, Farmington, Connecticut, USA
    Blood Press Monit 5:S17-23. 2000
    ..In the near future, the benefits of a chronotherapeutic approach to the management of hypertension should be elucidated by large-scale outcome studies...
  48. ncbi request reprint How well does ambulatory blood pressure predict target-organ disease and clinical outcome in patients with hypertension?
    W B White
    Section of Hypertension and Clinical Pharmacology, University of Connecticut School of Medicine, Farmington, CT 06030, USA
    Blood Press Monit 4:S17-21. 1999
    ..These data all support the desirability of increased utilization of 24 h ambulatory blood pressure monitoring in clinical trials of antihypertensive drugs and in the management of hypertensive patients in clinical practice...
  49. ncbi request reprint Chronopharmacology of cardiovascular therapy
    William B White
    Section of Hypertension and Clinical Pharmacology, Department of Medicine, University of Connecticut School of Medicine, Farmington 06030 3940, USA
    Blood Press Monit 7:199-207. 2002
  50. ncbi request reprint Preventing increases in early-morning blood pressure, heart rate, and the rate-pressure product with controlled onset extended release verapamil at bedtime versus enalapril, losartan, and placebo on arising
    William B White
    Section of Hypertension and Clinical Pharmacology, University of Connecticut School of Medicine, Farmington, Conn 06030 3940, USA
    Am Heart J 144:657-65. 2002
    ..Therapeutic agents for the treatment of hypertension may differ in their efficacy during the early-morning period, a time when both morbid and mortal cardiovascular events are increased compared with other times of the day...
  51. ncbi request reprint Systolic versus diastolic blood pressure versus pulse pressure
    William B White
    Section of Hypertension and Clinical Pharmacology, University of Connecticut School of Medicine, 263 Farmington Avenue, Farmington, CT 06030 3940, USA
    Curr Cardiol Rep 4:463-7. 2002
    ..At the present time, outcomes data have not been well established for reductions in pulse pressure in older patients with hypertension...
  52. doi request reprint Effects of telmisartan and amlodipine in combination on ambulatory blood pressure in stages 1-2 hypertension
    William B White
    Pat and Jim Calhoun Cardiology Center, University of Connecticut School of Medicine, Farmington, 06030, USA
    Blood Press Monit 15:205-12. 2010
    ..This is of clinical relevance because out-of-office BP values are of prognostic importance. We studied the effects of combining telmisartan and amlodipine on ambulatory BP in patients with stages 1-2 hypertension...
  53. ncbi request reprint Effects of the angiotensin II receptor blockers telmisartan versus valsartan on the circadian variation of blood pressure: impact on the early morning period
    William B White
    Section of Hypertension and Clinical Pharmacology, University of Connecticut School of Medicine, Farmington, Connecticut 06032, USA
    Am J Hypertens 17:347-53. 2004
    ....
  54. doi request reprint Effects of the angiotensin receptor blocker azilsartan medoxomil versus olmesartan and valsartan on ambulatory and clinic blood pressure in patients with stages 1 and 2 hypertension
    William B White
    Division of Hypertension and Clinical Pharmacology, Calhoun Cardiology Center, University of Connecticut Health Center, 263 Farmington Ave, Farmington, CT 06030 3940, USA
    Hypertension 57:413-20. 2011
    ..Azilsartan medoxomil could provide higher rates of hypertension control within the ARB class...
  55. doi request reprint Effects of naproxcinod on blood pressure in patients with osteoarthritis
    William B White
    Pat and Jim Calhoun Cardiology Center, University of Connecticut School of Medicine, Farmington, Connecticut, USA
    Am J Cardiol 107:1338-45. 2011
    ....
  56. doi request reprint Safety and tolerability of the direct renin inhibitor aliskiren in combination with angiotensin receptor blockers and thiazide diuretics: a pooled analysis of clinical experience of 12,942 patients
    William B White
    Division of Hypertension and Clinical Pharmacology, Calhoun Cardiology Center, University of Connecticut School of Medicine, Farmington, CT 06030 3940, USA
    J Clin Hypertens (Greenwich) 13:506-16. 2011
    ..The safety and tolerability profile of aliskiren in combination with the ARBs valsartan or losartan, or diuretic, is similar to aliskiren, ARBs, or diuretics alone...
  57. doi request reprint EXamination of cArdiovascular outcoMes with alogliptIN versus standard of carE in patients with type 2 diabetes mellitus and acute coronary syndrome (EXAMINE): a cardiovascular safety study of the dipeptidyl peptidase 4 inhibitor alogliptin in patients wi
    William B White
    University of Connecticut School of Medicine, Farmington, 06030 3940, USA
    Am Heart J 162:620-626.e1. 2011
    ..5% for the true HR. Study progress: More than 2,000 ACS patients were randomized as of June 2011. EXAMINE will define the CV safety profile of this dipeptidyl peptidase 4 inhibitor in patients at high risk for CV events...
  58. ncbi request reprint Comparative efficacy and safety of nisoldipine extended-release (ER) and amlodipine (CESNA-III study) in African American patients with hypertension
    William B White
    Section of Hypertension and Clinical Pharmacology, Department of Medicine, University of Connecticut School of Medicine, 263 Farmngton Avenue, Farmington, CT 06032, USA
    Am J Hypertens 16:739-45. 2003
    ....
  59. ncbi request reprint Cardiovascular thrombotic events in arthritis trials of the cyclooxygenase-2 inhibitor celecoxib
    William B White
    Division of Hypertension and Clinical Pharmacology, Department of Medicine, University of Connecticut School of Medicine, Farmington, Connecticut 06030 3940, USA
    Am J Cardiol 92:411-8. 2003
    ..These comparative analyses demonstrate no evidence of increased risk of cardiovascular thrombotic events associated with celecoxib compared with either conventional NSAIDs or placebo...
  60. pmc Average daily blood pressure, not office blood pressure, is associated with progression of cerebrovascular disease and cognitive decline in older people
    William B White
    Division of Hypertension and Clinical Pharmacology, Calhoun Cardiology Center, University of Connecticut School of Medicine, 263 Farmington Ave, Farmington, CT 06030 3940, USA
    Circulation 124:2312-9. 2011
    ..Little is known about the importance of BP on the progression of microvascular disease of the brain, which has been associated with functional decline in mobility and cognition in older people...
  61. ncbi request reprint Assessment of the novel selective aldosterone blocker eplerenone using ambulatory and clinical blood pressure in patients with systemic hypertension
    William B White
    Section of Hypertension and Clinical Pharmacology, University of Connecticut School of Medicine, Farmington, Connecticut 06030 3940, USA
    Am J Cardiol 92:38-42. 2003
    ..The top effective dose in stage 1 to 3 hypertension based on clinic and ambulatory BP was 100 mg once daily. The incidence of elevated serum potassium levels was not increased across doses of eplerenone in this study...
  62. doi request reprint A cardiovascular safety study of LibiGel (testosterone gel) in postmenopausal women with elevated cardiovascular risk and hypoactive sexual desire disorder
    William B White
    Division of Hypertension and Clinical Pharmacology, Calhoun Cardiology Center, University of Connecticut School of Medicine, Farmington, 06030 3940, USA
    Am Heart J 163:27-32. 2012
    ....
  63. ncbi request reprint Clinical trial experience around the globe: focus on calcium-channel blockers
    William B White
    Department of Medicine, Division of Hypertension and Clinical Pharmacology, Clinical Trials Unit, University of Connecticut School of Medicine, Farmington, Connecticut 06030 3940, USA
    Clin Cardiol 26:II7-11. 2003
    ..The evidence shows that calcium antagonists remain an important part of hypertension management, including in those individuals at risk of cardiac and cerebrovascular events...
  64. ncbi request reprint Circadian variation of blood pressure and the assessment of antihypertensive therapy
    W B White
    Section of Hypertension and Clinical Pharmacology, University of Connecticut School of Medicine, Farmington, CT 06032 3940, USA
    Blood Press Monit 4:S3-6. 1999
    ..In this review, we evaluate new data on the clinical impact of cardiovascular chronotherapy and the importance of timing of dosing on pharmacodynamics...
  65. ncbi request reprint Effects of tyramine administration in Parkinson's disease patients treated with selective MAO-B inhibitor rasagiline
    J Antonelle deMarcaida
    Department of Neurology, University of Connecticut, Farmington, Connecticut, USA
    Mov Disord 21:1716-21. 2006
    ..These data demonstrate that rasagiline 0.5 to 2 mg daily is not associated with clinically significant tyramine reactions and can be used as monotherapy or adjunct to levodopa in PD patients without specific dietary tyramine restriction...
  66. ncbi request reprint Comparative effects of telmisartan in the treatment of hypertension
    William B White
    Section of Hypertension and Clinical Pharmacology, University of Connecticut School of Medicine, Farmington, CT 06030 3940, USA
    J Clin Hypertens (Greenwich) 4:20-5. 2002
    ....
  67. ncbi request reprint Relevance of blood pressure variation in the circadian onset of cardiovascular events
    William B White
    University of Connecticut Health Center, Hypertension and Clinical Pharmacology, Farmington, Connecticut 06030, USA
    J Hypertens Suppl 21:S9-15. 2003
    ..Direct comparative studies with telmisartan and other angiotensin-II receptor blockers and with amlodipine have shown that telmisartan has a long duration of action and controls blood pressure over the 24-h dosing period...
  68. ncbi request reprint Effects of the selective aldosterone blocker eplerenone versus the calcium antagonist amlodipine in systolic hypertension
    William B White
    Section of Hypertension and Clinical Pharmacology, University of Connecticut School of Medicine, 263 Farmington Ave, Farmington, Conn 06030 3940, USA wwhite nso1 uchc edu
    Hypertension 41:1021-6. 2003
    ..Furthermore, eplerenone reduced microalbuminuria to a greater extent than amlodipine in this older patient group...
  69. ncbi request reprint Effects of drospirenone/17-beta estradiol on blood pressure and potassium balance in hypertensive postmenopausal women
    Richard A Preston
    Division of Clinical Pharmacology and Pharmacokinetics Clinical Research Center, Department of Medicine, University of Miami School of Medicine, Miami, Florida, USA
    Am J Hypertens 18:797-804. 2005
    ..Because of a significant aldosterone antagonist activity, we studied the effects of DRSP/E2 on serum potassium (K) and blood pressure (BP) in hypertensive postmenopausal women with and without diabetes mellitus...
  70. pmc Sleep-disordered breathing and 24-hour blood pressure pattern among older adults
    Yohannes W Endeshaw
    Division of Geriatrics and Gerontology, Department of Medicine, Emory University School of Medicine, 1841 Clifton Road NE, Atlanta, GA 30329, USA
    J Gerontol A Biol Sci Med Sci 64:280-5. 2009
    ..To examine the association between sleep-disordered breathing (SDB) and 24-hour blood pressure (BP) pattern among community-dwelling older adults...
  71. ncbi request reprint Relevance of blood pressure variation in the circadian onset of cardiovascular events
    William B White
    University of Connecticut Health Center, Hypertension and Clinical Pharmacology, Farmington, Connecticut 06030, USA
    J Hypertens Suppl 21:S9-15. 2003
    ..Direct comparative studies with telmisartan and other angiotensin-II receptor blockers and with amlodipine have shown that telmisartan has a long duration of action and controls blood pressure over the 24-h dosing period...
  72. ncbi request reprint Abnormalities in blood pressure regulation in a patient with Parkinson's disease
    Jose R Arias-Vera
    Section of Hypertension and Vascular Diseases, UCONN Health Center, University of Connecticut School of Medicine, Farmington, Connecticut 06032 3940, USA
    Am J Hypertens 16:612-3. 2003
  73. ncbi request reprint Drospirenone, a new progestogen, for postmenopausal women with hypertension
    Madhavi Mallareddy
    Division of Hypertension and Clinical Pharmacology, Pat and Jim Calhoun Cardiology Center, University of Connecticut School of Medicine, Farmington, Connecticut 06030 3940, USA
    Drugs Aging 24:453-66. 2007
    ..Thus, drospirenone is a unique progestogen that confers the additional benefit of BP reduction, an effect that could lead to potential benefit with respect to some cardiovascular risk concerns in women taking hormone therapy...
  74. doi request reprint Hypertension in the postpartum woman: clinical update for the hypertension specialist
    Nimrta Ghuman
    Division of Hypertension and Clinical Pharmacology, Pat and Jim Calhoun Cardiology Center, University of Connecticut School of Medicine, 263 Farmington Avenue, Farmington, CT 06030 3940, USA
    J Clin Hypertens (Greenwich) 11:726-33. 2009
    ..The purpose of this clinical review article is to provide an approach to the management of postpartum hypertension...
  75. ncbi request reprint Determinants of left atrial size in patients with newly diagnosed untreated hypertension
    George A Mansoor
    University of Connecticut Health Center, Farmington, Connecticut 06030, USA
    Blood Press Monit 8:3-7. 2003
    ..These data demonstrate that body mass index and left ventricular mass were the main correlates of left atrial size in patients with previously untreated stage I-II hypertension...
  76. ncbi request reprint COX-2 selective inhibitors and heart health
    Lee S Simon
    University of Connecticut Health Center, Farmington, CT 06030, USA
    Postgrad Med 117:7-20. 2005
    ..This review evaluates and differentiates the CV effects of COX-2 selective inhibitors through an assessment of prospective, randomized epidemiologic studies and meta-analyses...
  77. ncbi request reprint Self-measured home blood pressure in predicting ambulatory hypertension
    George A Mansoor
    Section of Hypertension and Clinical Pharmacology, University of Connecticut Health Center, Farmington, Connecticut, USA
    Am J Hypertens 17:1017-22. 2004
    ..However, some persons with home BP below this cut-off will have ambulatory hypertension. We therefore prospectively study the role of home BP in predicting ambulatory hypertension in persons with stage 1 and borderline hypertension...
  78. ncbi request reprint Importance of aggressive blood pressure lowering when it may matter most
    William B White
    Division of Hypertension and Clinical Pharmacology, Pat and Jim Calhoun Cardiology Center, University of Connecticut School of Medicine, Farmington, Connecticut 06032 3940, USA
    Am J Cardiol 100:10J-16J. 2007
    ..Studies of this nature can even assess blood pressure control in the early-morning period by sequestering data before and after awakening...
  79. doi request reprint The management of hyperkalemia in patients with cardiovascular disease
    Apurv Khanna
    Division of Hypertension and Clinical Pharmacology, Pat and Jim Calhoun Cardiology Center, University of Connecticut School of Medicine, Farmington, CT 06030 3940, USA
    Am J Med 122:215-21. 2009
    ..Management of hyperkalemia may be improved by identifying the levels of potassium that may potentially induce harm and using appropriate strategies to avert the levels that may be dangerous or life threatening...
  80. ncbi request reprint Primary hyperaldosteronism associated with hypertensive emergencies
    Paul T Labinson
    Section of Hypertension, Pat and Jim Calhoun Center for Cardiology, University of Connecticut Health Center, 263 Farmington Avenue, Farmington, CT 06030, USA
    Am J Hypertens 19:623-7. 2006
    ..The differential diagnosis of hypertensive emergencies should include primary hyperaldosteronism...
  81. ncbi request reprint Evaluation of recent fixed-dose combination therapies in the management of hypertension
    Apurv Khanna
    Division of Hypertension and Clinical Pharmacology, Pat and Jim Calhoun Cardiology Center, University of Connecticut School of Medicine, Farmington, Connecticut 06030 3940, USA
    Curr Opin Nephrol Hypertens 17:477-83. 2008
    ..This review discusses the drug combinations that have additive effects and those that do not provide additional benefit while increasing the adverse events...
  82. doi request reprint The importance of the clinical observer in the development of a white-coat effect in African-American patients with hypertension
    Paul T Labinson
    Section of Hypertension and Clinical Pharmacology, Center for Cardiology and Cardiovascular Biology, University of Connecticut School of Medicine, Farmington, Connecticut 06030 3949, USA
    Blood Press Monit 13:139-42. 2008
    ....
  83. ncbi request reprint Hypertension management: differing points of view: ambulatory blood pressure monitoring for every hypertensive patient: it's about time!: the argument against
    William B White
    Section of Hypertension and Clinical Pharmacology, Pat and Jim Calhoun Cardiology Center, University of Connecticut School of Medicine, Farmington, CT, USA
    J Clin Hypertens (Greenwich) 6:710-3; quiz 714. 2004
  84. ncbi request reprint Ambulatory blood pressure monitoring in chronic renal disease: technical aspects and clinical relevance
    Aldo J Peixoto
    Section of Nephrology, Yale University School of Medicine, New Haven, Connecticut, USA
    Curr Opin Nephrol Hypertens 11:507-16. 2002
    ..To evaluate the current value of ambulatory blood pressure monitoring in patients with chronic renal disease and end-stage renal disease...
  85. ncbi request reprint Simultaneous administration of vardenafil and tamsulosin does not induce clinically significant hypotension in patients with benign prostatic hyperplasia
    Stephen M Auerbach
    California Professional Research, Newport Beach, California 92660, USA
    Urology 64:998-1003; discussion 1003-4. 2004
    ..To assess the pharmacodynamic effects of coadministered vardenafil and tamsulosin in patients with benign prostatic hyperplasia (BPH) undergoing stable tamsulosin therapy...
  86. ncbi request reprint Effects of celecoxib and rofecoxib on blood pressure and edema in patients > or =65 years of age with systemic hypertension and osteoarthritis
    Andrew Whelton
    Universal Clinical Research Center, Inc, and The Johns Hopkins University School of Medicine, Baltimore, Maryland 21030 1603, USA
    Am J Cardiol 90:959-63. 2002
    ..7%) compared with the celecoxib group (4.7%) (p <0.05). Thus, in patients with controlled hypertension on a fixed antihypertensive regimen, careful monitoring of BP is warranted after the initiation of celecoxib or rofecoxib therapy...
  87. ncbi request reprint Principal results of the Controlled Onset Verapamil Investigation of Cardiovascular End Points (CONVINCE) trial
    Henry R Black
    Rush Medical College of Rush University, Chicago, IL 60612, USA
    JAMA 289:2073-82. 2003
    ..Hypertensive patients are often given a calcium antagonist to reduce cardiovascular disease risk, but the benefit compared with other drug classes is controversial...
  88. ncbi request reprint Debate: angiotensin-converting enzyme inhibitors versus angiotensin II receptor blockers--a gap in evidence-based medicine
    Stephen G Ball
    Department of Cardiovascular Medicine, University of Leeds, Leeds, United Kingdom
    Am J Cardiol 91:15G-21G. 2003
    ....
  89. ncbi request reprint An effectiveness study comparing algorithm-based antihypertensive therapy with previous treatments using conventional and ambulatory blood pressure measurements
    Michael A Weber
    SUNY Downstate Medical School, Brooklyn, NY 11203, USA
    J Clin Hypertens (Greenwich) 8:241-50; quiz 251-2. 2006
    ..A treatment algorithm based on the angiotensin receptor blocker, telmisartan, was confirmed by the blinded end point of ABPM as an efficacious alternative to other antihypertensive regimens in clinical practice...
  90. ncbi request reprint Comparative antihypertensive efficacy of angiotensin receptor blocker-based treatment in African-American and white patients
    George L Bakris
    Department of Preventive Medicine, Rush University Medical Center, Chicago, IL 60612, USA
    J Clin Hypertens (Greenwich) 7:587-95; quiz 596-7. 2005
    ..We conclude that an angiotensin receptor blocker as part of a BP-lowering strategy is effective in previously untreated African-American patients, although a higher proportion will require the use of a diuretic compared with Caucasians...
  91. ncbi request reprint Improving the utility of the nocturnal hypertension definition by using absolute sleep blood pressure rather than the "dipping" proportion
    William B White
    Am J Cardiol 92:1439-41. 2003
  92. ncbi request reprint The use of peridialysis blood pressure and intradialytic blood pressure changes in the prediction of interdialytic blood pressure in haemodialysis patients
    Roger B Mendes
    GAMEN Grupo de Assistencia Medica e Nefrologica, Rio de Janeiro, Brazil
    Blood Press Monit 8:243-8. 2003
    ..The purpose of this study was to verify the power of peridialysis blood pressure to predict interdialytic blood pressure, and to ascertain the influence of blood pressure fluctuations during dialysis on this predictive ability...
  93. ncbi request reprint Effects of eplerenone versus losartan in patients with low-renin hypertension
    Myron H Weinberger
    Hypertension Research Center, Indiana University School of Medicine, Indianapolis, IN 46202 5111, USA
    Am Heart J 150:426-33. 2005
    ..Agents that block aldosterone at its receptor sites, therefore, should have significant clinical benefit in patients with low-renin hypertension...
  94. ncbi request reprint Hypertension associated with therapies to treat arthritis and pain
    William B White
    Hypertension 44:123-4. 2004
  95. ncbi request reprint Sustained antihypertensive activity of telmisartan compared with valsartan
    Yves Lacourciere
    Hypertension Research Unit, Centre Hospitalier l Université de Quebec, Ste Foy, Quebec, Canada
    Blood Press Monit 9:203-10. 2004
    ..The efficacies of the long half-life telmisartan compared with shorter half-life valsartan in the last 6 h of the dosing interval following active treatment and during 24 h after a missed dose were compared...
  96. doi request reprint Management of hypertension in patients with enhanced cardiovascular risk. Introduction
    William B White
    Am J Med 121:S1. 2008
  97. ncbi request reprint Effects of telmisartan 80 mg and valsartan 160 mg on ambulatory blood pressure in patients with essential hypertension
    William B White
    J Hypertens 22:2035-6; author reply 2036-8. 2004
  98. ncbi request reprint The Effects of cyclooxygenase-2 inhibitors and nonsteroidal anti-inflammatory therapy on 24-hour blood pressure in patients with hypertension, osteoarthritis, and type 2 diabetes mellitus
    James R Sowers
    State University of New York, Brooklyn, USA
    Arch Intern Med 165:161-8. 2005
    ..Therefore, we conducted a double-blind, randomized trial to evaluate the effects of celecoxib, rofecoxib, and naproxen on 24-hour blood pressure (BP) in patients with type 2 diabetes, hypertension, and osteoarthritis...
  99. ncbi request reprint Controversies in COX-2 selective inhibition
    Lee S Simon
    Beth Israel Deaconess Medical Center, Boston, MA 02215, USA
    J Rheumatol 29:1501-10. 2002

Research Grants3

  1. Contingency Management for Initiating Smoking Abstinence
    William White; Fiscal Year: 2008
    ..Clinic and 24-hour blood pressure (BP) and heart rate (HR) will be additional outcomes. We expect that BP and HR will decrease more among CM than non-CM patients and reductions in smoking may mediate decreases in these indices. ..
  2. Contingency Management for Initiating Smoking Abstinence
    William White; Fiscal Year: 2009
    ..Clinic and 24-hour blood pressure (BP) and heart rate (HR) will be additional outcomes. We expect that BP and HR will decrease more among CM than non-CM patients and reductions in smoking may mediate decreases in these indices. ..
  3. Contingency Management for Initiating Smoking Abstinence
    WILLIAM BARRY WHITE; Fiscal Year: 2010
    ..Clinic and 24-hour blood pressure (BP) and heart rate (HR) will be additional outcomes. We expect that BP and HR will decrease more among CM than non-CM patients and reductions in smoking may mediate decreases in these indices. ..